Lysosomal substrate

Lysosomal substrates are a broad category of biological macromolecules—including lipids, proteins, complex carbohydrates, and nucleic acids—that are delivered to the lysosome for enzymatic degradation and recycling [1, 11]. Under normal physiological conditions, these substrates enter the lysosome through endocytic, phagocytic, or autophagic pathways and are broken down by roughly 60 different acidic hydrolases into basic building blocks like amino acids and simple sugars [5, 14]. The clinical significance of these substrates is most prominent in lysosomal storage diseases (LSDs), where genetic mutations in hydrolases or transport proteins lead to the progressive and pathological accumulation of undigested material [7, 12]. This buildup disrupts cellular homeostasis, impairs vesicular trafficking, and triggers inflammatory cascades that lead to organ dysfunction and neurodegeneration [10, 12]. Therapeutic strategies typically focus on managing substrate levels by either providing functional recombinant enzymes through Enzyme Replacement Therapy (ERT) or inhibiting the biosynthesis of the substrates via Substrate Reduction Therapy (SRT) [3, 6, 13]. Understanding the dynamics of lysosomal substrate processing is essential for addressing both rare metabolic disorders and common age-related conditions characterized by lysosomal dysfunction [2, 4].

Other names

Lysosomal substratesLysosomal cargoLysosomal storage materialIntraluminal substratesMacromolecular substrates

Modulation of intralysosomal levels through Enzyme Replacement Therapy (ERT) to degrade accumulated material, Substrate Reduction Therapy (SRT) to inhibit biosynthesis of the substrates, or Pharmacological Chaperone Therapy (PCT) to stabilize endogenous degradative enzymes.